Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use
To the Editor: Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer. 1 – 4 We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2000-09, Vol.343 (10), p.740-741 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 741 |
|---|---|
| container_issue | 10 |
| container_start_page | 740 |
| container_title | The New England journal of medicine |
| container_volume | 343 |
| creator | Walkhom, Bandana Henner, William David Fraunfelder, F.T |
| description | To the Editor:
Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.
1
–
4
We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.
Patient 1 was a 48-year-old woman with metastatic breast cancer, a history of keratoconjunctivitis sicca, and 20/20 visual acuity in each eye who had severe bilateral irritation and decreased vision after two cycles of capecitabine (4600 mg per day for 14 days and 3000 mg per day for 14 days). Her visual acuity decreased to 20/40 . . . |
| doi_str_mv | 10.1056/NEJM200009073431015 |
| format | Article |
| fullrecord | <record><control><sourceid>mms_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1056_NEJM200009073431015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NJ200009073431015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-34ea95874c9347cb307ee245d798a45aabb86fa604b637b991e20dd8b4c31e4f3</originalsourceid><addsrcrecordid>eNp9kL1OwzAURi0EoqXwBEjIOwrY8U0cj1UoUFTaATpHtnMjXDU_sgOItydVGBgQd7nLOd9wCLnk7IazJL1dL56eYzacYlKA4IwnR2TKEyEiAJYekyljcRaBVGJCzkLYHVgO6pRMOFNSSZlOyfoFP9Aj3dj3vfZ06b3rde_ahuqmpHnrG9R7eoddG1wf6DyE1jrdY0k_Xf9Gc92hHQzjGqTbgOfkpNL7gBc_f0a294vX_DFabR6W-XwVWZGpPhKAWiWZBKsESGsEk4gxJKVUmYZEa2OytNIpA5MKaZTiGLOyzAxYwREqMSNi3LW-DcFjVXTe1dp_FZwVhzrFH3UG62q0undTY_nLGXMMwPUI1HUoGtzV_859AyGza9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Walkhom, Bandana ; Henner, William David ; Fraunfelder, F.T</creator><creatorcontrib>Walkhom, Bandana ; Henner, William David ; Fraunfelder, F.T</creatorcontrib><description>To the Editor:
Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.
1
–
4
We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.
Patient 1 was a 48-year-old woman with metastatic breast cancer, a history of keratoconjunctivitis sicca, and 20/20 visual acuity in each eye who had severe bilateral irritation and decreased vision after two cycles of capecitabine (4600 mg per day for 14 days and 3000 mg per day for 14 days). Her visual acuity decreased to 20/40 . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200009073431015</identifier><identifier>PMID: 10979776</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antineoplastic Agents - adverse effects ; Breast Neoplasms - secondary ; Capecitabine ; Corneal Diseases - chemically induced ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Female ; Fluorouracil - analogs & derivatives ; Humans ; Keratitis - chemically induced ; Keratoconjunctivitis Sicca - complications ; Middle Aged ; Visual Acuity - drug effects</subject><ispartof>The New England journal of medicine, 2000-09, Vol.343 (10), p.740-741</ispartof><rights>Copyright © 2000 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-34ea95874c9347cb307ee245d798a45aabb86fa604b637b991e20dd8b4c31e4f3</citedby><cites>FETCH-LOGICAL-c389t-34ea95874c9347cb307ee245d798a45aabb86fa604b637b991e20dd8b4c31e4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200009073431015$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200009073431015$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52361,54043</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10979776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walkhom, Bandana</creatorcontrib><creatorcontrib>Henner, William David</creatorcontrib><creatorcontrib>Fraunfelder, F.T</creatorcontrib><title>Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.
1
–
4
We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.
Patient 1 was a 48-year-old woman with metastatic breast cancer, a history of keratoconjunctivitis sicca, and 20/20 visual acuity in each eye who had severe bilateral irritation and decreased vision after two cycles of capecitabine (4600 mg per day for 14 days and 3000 mg per day for 14 days). Her visual acuity decreased to 20/40 . . .</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Breast Neoplasms - secondary</subject><subject>Capecitabine</subject><subject>Corneal Diseases - chemically induced</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Humans</subject><subject>Keratitis - chemically induced</subject><subject>Keratoconjunctivitis Sicca - complications</subject><subject>Middle Aged</subject><subject>Visual Acuity - drug effects</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1OwzAURi0EoqXwBEjIOwrY8U0cj1UoUFTaATpHtnMjXDU_sgOItydVGBgQd7nLOd9wCLnk7IazJL1dL56eYzacYlKA4IwnR2TKEyEiAJYekyljcRaBVGJCzkLYHVgO6pRMOFNSSZlOyfoFP9Aj3dj3vfZ06b3rde_ahuqmpHnrG9R7eoddG1wf6DyE1jrdY0k_Xf9Gc92hHQzjGqTbgOfkpNL7gBc_f0a294vX_DFabR6W-XwVWZGpPhKAWiWZBKsESGsEk4gxJKVUmYZEa2OytNIpA5MKaZTiGLOyzAxYwREqMSNi3LW-DcFjVXTe1dp_FZwVhzrFH3UG62q0undTY_nLGXMMwPUI1HUoGtzV_859AyGza9Y</recordid><startdate>20000907</startdate><enddate>20000907</enddate><creator>Walkhom, Bandana</creator><creator>Henner, William David</creator><creator>Fraunfelder, F.T</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20000907</creationdate><title>Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use</title><author>Walkhom, Bandana ; Henner, William David ; Fraunfelder, F.T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-34ea95874c9347cb307ee245d798a45aabb86fa604b637b991e20dd8b4c31e4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Breast Neoplasms - secondary</topic><topic>Capecitabine</topic><topic>Corneal Diseases - chemically induced</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Humans</topic><topic>Keratitis - chemically induced</topic><topic>Keratoconjunctivitis Sicca - complications</topic><topic>Middle Aged</topic><topic>Visual Acuity - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walkhom, Bandana</creatorcontrib><creatorcontrib>Henner, William David</creatorcontrib><creatorcontrib>Fraunfelder, F.T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walkhom, Bandana</au><au>Henner, William David</au><au>Fraunfelder, F.T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2000-09-07</date><risdate>2000</risdate><volume>343</volume><issue>10</issue><spage>740</spage><epage>741</epage><pages>740-741</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.
1
–
4
We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.
Patient 1 was a 48-year-old woman with metastatic breast cancer, a history of keratoconjunctivitis sicca, and 20/20 visual acuity in each eye who had severe bilateral irritation and decreased vision after two cycles of capecitabine (4600 mg per day for 14 days and 3000 mg per day for 14 days). Her visual acuity decreased to 20/40 . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>10979776</pmid><doi>10.1056/NEJM200009073431015</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2000-09, Vol.343 (10), p.740-741 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_crossref_primary_10_1056_NEJM200009073431015 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antineoplastic Agents - adverse effects Breast Neoplasms - secondary Capecitabine Corneal Diseases - chemically induced Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Female Fluorouracil - analogs & derivatives Humans Keratitis - chemically induced Keratoconjunctivitis Sicca - complications Middle Aged Visual Acuity - drug effects |
| title | Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A04%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-mms_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20Ocular%20Irritation%20and%20Corneal%20Deposits%20Associated%20with%20Capecitabine%20Use&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Walkhom,%20Bandana&rft.date=2000-09-07&rft.volume=343&rft.issue=10&rft.spage=740&rft.epage=741&rft.pages=740-741&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM200009073431015&rft_dat=%3Cmms_cross%3ENJ200009073431015%3C/mms_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10979776&rfr_iscdi=true |